Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum β2-microglobulin

American Journal of Clinical Pathology

Volumn 106, Issue 1, 1996, Pages 64-68

  Schambeck, Christian M ^a,b   Bartl, Reiner ^a   Höchtlen Vollmar, Wilma ^a   Wick, Manfred ^a   Lamerz, Rolf ^a   Fateh Moghadam, Ahmad ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

B 2 microglobulin; Histology; Myeloma; Proliferation

Indexed keywords

BETA 2 MICROGLOBULIN;

ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL STRUCTURE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LABELING INDEX; MYELOMA; PRIORITY JOURNAL;

EID: 0029927223     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/106.1.64     Document Type: Article

References (16)

1. Durie BGM, Salmon SE, Moon TE. Pretreatment tumor mass, cell kinetics and prognosis in multiple myeloma. Blood 1980; 55: 364-372.
2. Hofmann V, Salmon SE, Durie BGM. Drug resistance in multiple myeloma associated with in vitro incorporation of 3 H-thymidine. Blood 1981;58:471-476.
3. Latreille J, Barlogie B, Johnston D, Drewinko B, Alexanian R. Ploidy and proliferative characteristics in monoclonal gammopathies. Blood 1982;59:43-51.
4. Bartl R, Frisch B, Fateh-Moghadam A, et al. Histologic classification and staging in multiple myeloma. Am J Clin Pathol 1987;87:342-355.
5. 2 microglobulin in myeloma: A southwest oncology group study. Blood 1990;75:823-830.
6. 2 microglobulin and thymidine kinase. The Clinical Investigator 1993;71:918-923.
7. Schambeck CM, Wick M, Bartl R, Lamerz R, Fateh-Moghadam A. Plasma cell proliferation in monoclonal gammopathies: Measurement using BU-1 antibody in flow cytometry and microscopy: Comparison with serum thymidine kinase. J Clin Pathol 1995;48:477-481.
8. Durie BGM, Salmon SE. A clinical staging system for myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-854.
9. Greipp PR, Raymond NM, Kyle RA, O'Fallon WM. Multiple myeloma: Significance of plasmablastic subtype in morphological classification. Blood 1985;65:305-310.
10. Moro MJ, Portero JA, Gascon A, et al. Utilidad del examen de la morfologia de la celula plasmatica en el estudio del mieloma multiple. Sangre-Barc 1992;37:175-179.
11. Sukpanichnant S, Cousar JB, Leelasiri A, et al. Diagnostic criteria and histologic grading in multiple myeloma: Histologic and immunohistologic analysis of 176 cases with clinical correlation. Hum Pathol 1994;25:308-318.
12. 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993;81:3382-3387.
13. Ffrench M, Ffrench P, Remy F, et al. Plasma cell proliferation in monoclonal gammopathy: Relations with other biologic variables - Diagnostic and prognostic significance. Am J Med 1995;98:60-66.
14. 2 microglobulin in monoclonal gammopathies. Acta Haematol 1987;78:239-242.
15. 2 microglobulin in multiple myeloma: A new prognostic strategy. Eur J Haematol 1989;51(suppl):88-98.
16. Bartl R, Frisch B, Diem H, et al. Histologic, biochemical, and clinical parameters for monitoring multiple myeloma. Cancer 1991;68:2241-2250.